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Summary: Immunpluimnometric assays for lactoferrin and elastase-cti-proteinase inhibitor complexes were
developed using solid-phase methodology, which has already been published from this laboratory. The aim
of the study was to develop ä rapid method to see whether elevated granulocyte activity was present in the
lung, as for example in neonatal sepsis. The lactoferrin assay gave reliable results within 30 minutes, the
elastase^ttt-proteinase inhibitor complexes, within 5 hours.
The correlation between both analytes was good, so that the lactoferrin assay could replace the elastase-ar
proteinase inhibitor assay in emergency cases. The lactoferrin assay was used for rapid answer, the elastase-
-pröteinase inhibitor complex assay for "fine" monitoring of the progress of the disease. Both assays could
be used to measure concentrations in plasma or bronchoalveolar lavage using a 10 sample. Plasma for the
elastase-aj-proteinase inhibitor complex determination had to be diluted 1:50 before being assayed.
Only EDTA plasma was used in the assay, as either heparin plasma or serum resulted in granulocyte
destruction, thus giving rise to elevated, and non-reproducible results.
The results from bronchoalveolar lavage show an excellent correlation between elastase-dj-proteinase inhibitor
complexes and lactoferrin.
No interference was seen from lipaemic or icteric plasma samples. Results from haemolytic samples i. e. where
lysis of erythrocytes and leukocytes had occurred, had to be treated with care if no clinical indication of
intravascular haemorrhage was present. The assays lend themselves to perinatal diagnosis, as the total volume
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of plasma or lavage needed is theoretically under 50 μΐ, i. e. ethically acceptable for regular monitoring of
neonates. As far as could be determined, both assays were specific and robust.
The elastase-ctj-proteinase inhibitor immunoluminometric assay correlated well with the commercial ELISA
test kit in EDTA plasma (ELISA = (0.93 χ ILMA) -41, η =* 52, r = 0.93) showing that both assays
measured similar complexes.
Introduction
It is often difficult to determine causes of lung dys-
function and sepsis in neonates. The aim of this study
was to combine the sensitivity of luminescent detec-
tion systems and the specificity of leukocyte analytes
(in this case, elastase and lactoferrin) for use in a
paediatric clinic and intensive care unit.
We describe the development and clinical evaluation
of immunoluminometric assays for lactoferrin and
elastase-ttj-proteinase inhibitor complexes in plasma
and bronchoalveolar lavage samples.
Both analytes monitor granulocyte activity (1—3),
and are useful in monitoring inflammatory disease
with possible bacterial involvement, where other an-
alytes, for example C-reactive protein alone, provide
insufficient data. In this article special mention is
made of lung diseases, especially pneumonia and neo-
natal sepsis. Since the assay is very sensitive, requiring
a sample volume of less than 50 μΐ for the determi-
nation of both components, both tests are suitable
for perinatal diagnosis and monitoring.
The elastase is present in the primary vesicles of
polymorphonuclear leukocytes (4) and is set free dur-
ing normal or "frustrated" phagocytosis or cell de-
struction. Lactoferrin is not only present in polymor-
phonuclear leukocytes (5), but is also present in pan-
creatic juice (6), milk (7) and synovial fluid (5), so
that the determination in plasma is not as specific as
that of elastase-drproteinase inhibitor complexes.
Theoretically all body fluids are suitable for the de-
termination of elastase complexes and lactoferrin, de-
pendent upon the site of inflammation. Bronchoal-
veolar lavage may form the ideal sample if granulo-
cyte activity is to be monitored in respiratory disease.
EDTA plasma was the material of choice for blood
concentration measurements (8). Although in practice
citrate and oxalate plasma could be used, the dilution
factor (1 part citrate/oxalate -f- 9 parts blood) must
be taken into consideration. A commercial enzyme
immunoassay (PMN-Elastase ELISA, Merck,
Darmstadt, D), which requires regular routine expe-
rience to obtain optimal results, is available for meas-
uring elastase-ai-proteinase inhibitor complexes. The
results for the Merck test are available about 6 hours
after taking the sample.
A solid-phase radioimmunoassay for lactoferrin has
been published by Bennett & Mohle (9), in which
serum concentrations were higher than plasma con-
centrations, and in which the "leak" process was
followed in serum, heparin and EDTA plasma over
several hours.
The assays developed and validated in the present
work are suitably robust and reproducible for routine
use, and do not involve the use of a radioactive label.
Materials and Methods
Immunoluminometric assays using polystyrene balls as solid-
phase have been published previously from this laboratory
(10-14).
Antisera
Antiserum to ctj-proteinase inhibitor was purchased from Cap-
pel Laboratories (Organon Teknika N.V., Turahout, B).
Antiserum to human elastase was obtained from Serotec (Ca-
mon GmbH, Wiesbaden, D).
The two antisera for the lactoferrin assay were obtained from
Cappel and Dakopatts (Hamburg, D) respectively.
Polystyrene balls (6.4 mm diameter) were bought from Sphero^
tech Kugeln (Fulda, D).
Antibodies were labelled with N-(7-(4-aminobutyl-N-ethyl) na-
phthalene-l,2-dicarboxylic acid hydrazide) hemisuccinamide
(ABEN-H) as previously published (10).
Standards
Lactoferrin and a\-antitrypsin (arproteinase inhibitor) were
obtained from Sigma, Deisenhofen, D, elastase from Protogeh,
L ufelfingen, CH.
The elastase standard was complexed with an excess of purified
cti-proteinase inhibitor in a molar ratio of 1:35 (i.e. under
physiological conditions). Complex formation was monitored
by loss of elastase activity, determined photometrically with the
synthetic substrate Me-O-Suc-(Ala)2-Pro-Val-nitroanilide
(Bachern, Bubendorf, CH). The nominal values of the elastase-
ctj-proteinase inhibitor are given in terms of the elastase content.
Lactoferrin standards were made up in foetal calf serum as this
was shown to be free of immunoreactive lactoferrin.
Samples
EDTA blood samples were obtained from patients with and
without lung infections, as well as from healthy blood donors
with normal blood sedimentation rate, normal blood smear,
aminotransferases and γ-glutamyl transferase. The blood sam-
ples were left to stand for 30 minutes at 4°C before being
centrifuged at 2000 £ for 10 min. Ttie' supernatant was then
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removed, portioned and stored at —20 °C until assayed. Full
EDTA blood samples older than 2 hours could not be used as
the "leak process" had already started, giving rise to falsely
elevated results.
Bronchoalveolar lavage was obtained from different patient
groups, using a published standardised method (15).
Tables la and Ib show the assay schemes for the elastase-ar
proteinase inhibitor complex assay (PMN-Elastase) from
Merck, (Darmstadt, D) and the immunoluminometric assay
developed in this laboratory.
Table Ic shows the assay flow-diagram for the lactoferrin im-
munoluminometric assay.
Tab. la. Flow diagram of the Merck PMN-Elastase-Enzyme-
Immunoassay
1000 μΐ wash solution.
1 coated tube.
5—20 minutes incubation at 20—25 °C.
Aspirate.
500 μΐ sample (1:50 dilution).
500 μΐ dilution buffer.
l h incubation at 20-25 °C, then
wash with 3 χ 1 ml wash solution.
500 μΐ antibody-enzyme solution (alkaline phosphatase).
1 h incubation at 20-25 °C.
2 ml wash solution.
Stand for 10 min and aspirate.
500 μΐ substrate solution.
1.5 h incubation at 20—25 °C.
Add 500 μΐ stop solution (2 mol/1 NaOH)
and measure absorbance at 405 nm
Tab. Ib. Flow diagram of the elastase-tt!-proteinase inhibitor
complex Immunoluminometric Assay (ILMA)
200 μΐ sample/standard (plasma 1 = 50 dil., lavage 1:1 — 1:25
dil.)
1 anti human PMN-elastase-coated ball.
3 h incubation at room temperature on horizontal rotator
(170 min-1).
Wash with 2 χ 5 ml 0.25 ml/1 Tween 20.
200 μΐ ABEI-labelled anti-di-proteinase inhibitor in assay
buffer*).
2 h incubation (process as above).
Transfer ball to measuring cuvette,
add 300 μΐ catalyst solution,
load luminometer (LB 950 or LB 952) and initiate light reaction
with 300 μΐ alkaline peroxide.
Integrate light signal over 10 or 2 s respectively.
Tab. Ic. Flow diagram of the Lactoferrin ILMA
10 μΐ sample/standard.
200 μΐ Anti-Lactofemn-ABEN (Dako) in assay buffer*).
1 Anti-Lactoferrin-coated ball (Cappel).
Incubate 30 min on horizontal rotator (170 min"1) and process
as in table Ib
*) assay buffer:
0.025 mol/1 phosphate, 0.15 mol/1 sodium chloride, 0.25 ml/1
Tween 20, pH 7.6.
Instruments
All measurements were performed on either an LB 950 or LB
952 automated luminometer (Laboratorium Prof. Dr. Berthold,
Wildbad, D) using a 2 s integral (LB 952) or a 10 s integral (LB
950) time. Both luminometers had a capacity of 250 samples.
Horizontal rotators (Heidolph Horizontalrotierer, Abbott,
Wiesbaden, D) were used for the incubation steps. The washing
procedures were performed using an automatic washing system
(Pentawash or Pro-quantum, Abbott, Wiesbaden, D).
Results
Table 2 shows the imprecision using compound pre-
cision profiles and inter-assay imprecision for both
assays.
Figure 1 shows typical standard curves for elastase-
ct!-proteinase inhibitor and lactoferrin assays, respec-
tively.
The effect of 5 different dilution media for the elas-
tase-cti-proteinase inhibitor assay was tested, the re-
sults being shown in table 3.
Recovery experiments were carried out on two plasma
samples with low and high concentrations, the results
being listed in table 4. The elastase-at- proteinase
inhibitor recovery was determined additively, the lac-
.toferrin recovery by using an admixture of 2 samples.
In addition the mean recovery of elastase from the
addition of two plasma samples was measured in 8
consecutive assays: Plasma 1 — 9 8 μg/l, Plasma 2 —
347 μg/l. Expected value — 445 μg/l, mean value
found — 472 μ§/1, mean recovery 106%.
Tab. 2. Imprecision data for elastase-d! -proteinase inhibitor
complex and lactoferrin assays (mean of duplicate val-
ues used for calculation)
a) Precision profiles
1) Elastase complex (24 assays)
50-500 μg/l η = 319 CV = 5.17%
> 600 pg/1 η = 130 CV = 4.72%
2) Lactoferrin (22 assays)
0.1-1 mg/1 n = 469 CV = 5.80%
> l mg/1 n = 41 CV = 4.92%
b) Interassay variation
(derived from means of duplicate determinations)
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Fig. 1. Standard curves of both assays, performed as described
in tables 4fc + Ic.
The units on the ordinate are relative light units and
are directly proportional to the number of photons
emitted. The standard concentrations can be seen on
the abscissa.
The mean lower detection limit of the elastase-di-
proteinase inhibitor complex assay, measured as μg/l
elastase was 0.3 μ§/1 (12 fg/tube) (or in the plasma
assay 15 μ§/1 — allowing for the 50-fold sample
dilution).
This represented the mean + 3 s value of the zero
standard read from 20 standard curves. This value
did not overlap the — 3 s value of the first standard
point. For lactoferrin in a similar study, the mean
lowest detection limit was 0.04 mg/1 (0.4 pg/tube)
using a 10 μΐ plasma sample.
Lipaemic and icteric sera did not interfere in the assay,
probably due, amongst other things, to the small
sample volume (less than 4% of the total incubation
volume).
Haemolysed samples were discarded unless intravas-
cular haemolysis was expected or was not to be ex-
cluded (e.g. Rh-erythroblastosis). These findings
comply with those of Neumeier et al. (17). Purified
haemoglobin did not affect the results of other assays
when added to the plasma sample to be measured at
a concentration of 1 g/1.
The specificity of the elastase assay was tested with
pure human α,-proteinase inhibitor (Sigma) com-
plexed with human pancreatic elastase and porcine
pancreatic elastase. Neither preparation reacted in the
assay even at concentrations of 20 mg/1 elastase com-
plexes.
Tab. 3. Effect of dilution media on the shape of the standard
curve and the results read from the relevant curve for

























































































































Results are the mean of 5 assays set up on consecutive days
Buffer 1: PMN-Elastase, Merck Immunoassay, kit^-buffer
Buffer 2: 0.15 mol/1 NaCl, 0.025 mol/1 phosphate with 1 g/1
ovalbumin
Buffer 3: 0.15 mol/1 NaCl, 0.025 mol/1 phosphate, 0.15 ml/1
Tween
Buffer 4: 0.15 mol/1 NaCl, with 150 g/1 bovine serum albumin
Buffer 5: 0.15 mol/1 NaCl, 0.025 mol/1 phosphate, 0.05 mol/1
Tris-HCl 1:1 mixture containing 2.5 g/1 bovine serum
albumin, 0.15 ml/1 Tween
All buffers had a pH of 7.6.
Tab. 4. Recovery studies on the elastase-arproteinase inhibitor
complex and lactoferrin concentrations in plasma sam-
ples.
1. Elastase-OLi-proteinase inhibitor
Mean recovery at 4 dilutions of one plasma added to a constant
amount of a second plasma sample. Mean results from 4 assays,
































Mean recovery from an admixture of two plasma samples.
Results from 5 assays, plasma 5 — 1.25 mg/1, plasma 2 — 0.12
mg/1.
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The lactoferrin assay was specific for lactoferrin and
did not cross-react with transferrin, even when the
latter was present at a concentration of 10 g/1.
In the lactoferrin assay, the same results were obtained
after 30, 60 and 90 minutes incubation times
(y = a + bx) n = 25 different plasma samples in each
case. For 30 min v 60 min r = 0.988; ayx ~ 0.002;
byx = 0.981. This validation data was needed to
reduce the time between taking the sample and re-
ceiving the results.
Table 5a shows the reference range established for
elastase-arproteinase inhibitor complexes in EDTA
plasma from healthy blood donors and the concen-
trations of this analyte in dialysis patient plasma.
Table 5b shows the same for lactoferrin values in
EDTA plasma and in serum taken after the blood
had been allowed to clot for at least 30 minutes. The
difference between plasma and serum was statistically
significant for lactoferrin (Mann-Whitney U-test:
z = 3.94, p < 0.01).
The difference before and after dialysis was statisti-
cally significant for both elastase and lactoferrin (Wil-
coxon signed rank test: ca elastase = 6.23, ca lacto-
ferrin = 5.90, p < 0.01 in both cases).
Tab. 5. Concentrations of elastase-arproteinase inhibitor com-
plexes and lactoferrin in plasma from uraemic patients
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Fig. 2. Serial dilution in 0.15 mol/1 NaCl of a leukocyte prep-
aration. The concentration of elastase-arproteinase in-
hibitor complexes and lactoferrin in the lysate (2x freeze-
thaw-cycles) is shown on the ordinate (values for both
analytes in μ§/1). The numbers of leukocytes per liter is
shown on the abscissa.
Figure 2 shows the correlation of elastase (measured
in complex with added arproteinase inhibitor) and
lactoferrin in the supernate of a leukocyte preparation
after serial dilution, centrifugation, and two freeze-
thaw cycles. Before freezing and thawing, the super-
nate contained no measurable elastase or lactoferrin.
Figure 3 shows the values for elastase at-proteinase
inhibitor and lactoferrin in bronchoalveolar lavage in
selected patients with chronic obstructive lung disease
and bacterial pneumonia. The median concentration
of elastase was 223 μg/l (range 230 — 1320) and of
lactoferrin 0.20 mg/1 (range < 0.05-3.05 mg/1). Fig-
ure 4 shows the correlation between the commercial
enzyme immunoassay and the luminescent immu-
noassay in plasma from healthy and diseased patients.
Discussion
Lactoferrin can be determined rapidly and usually
correlates with elastase concentrations, when the lat-
ter is determined in a complex with arproteinase
inhibitor (see tab. 5 and fig. 2). The lactoferrin results
can be returned to the ward within one hour, which
is important in the treatment of neonatal sepsis cases.
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 10
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Fig. 3. Bronchoalveolar lavage from 12 patients with bacterial pneumonia (patients 1 — 12) and 10 patients with other chronic
obstructive lung disease without bacterial involvement (patients 13—22). Concentrations of elastase-arproteinase inhibitor
complexes (expressed as μg/l elastase) and lactoferrin are shown in the ascending columns. The number of polymorpho-
nuclear leukocytes, shown in the descending columns, is expressed as a fraction of the total cells found in the aspiration
fluid. The data for the regression lines y = a + bx and χ = a + by (elastase complex = x, lactoferrin = y) are: correlation
coefficient r = 0.900,
ayx = 0.194, byx = 0.003
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Fig. 4. Correlation between the Merck enzyme immunoassay
(ELISA) and immtmoluminometric assay (ILMA) for
the determination of elastase-Qj-proteinase inhibitor
complexes in body fluids. Data for 52 EDTA plasma
samples taken from children aged 0—12 months.ELISA
= 0.931 χ ILMA - 43
It has been shown that lactoferrin is present in other
body fluids and organs such as milk (7) and pancreas
juice (6), so that plasma concentrations do not orig-
inate entirely from granulocyte destruction as in the
case of granulocyte elastase. Although pancreatic elas-
tase is also released in small amounts into the blood-
stream, it does not react in this assay.
Both assays are simple to perform and are specific,
sensitive and reproducible enough for determinations
in plasma or lung lavage. The elastase ILMA is sim-
pler to carry out than the elastase ELISA (see tab. la
and Ib) because of the fewer wash and incubation
steps.
The determination in bronchoalveolar lavage is the-
oretically more specific for lung sepsis cases because
additional sources of elastase and lactoferrin are ex-
cluded, and because the concentrations are measured
at the "site of action". Attempts at standardising the
lactoferrin and elastase complex*concentrations by
relating them to albumin or urea in the bronchoal-
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veolar lavage were abandoned as no improvement in
separation between non-sepsis and sepsis groups was
seen. This is in agreement with other findings (13,15)
for proteins in lavage.
The choice of assay buffer for the elastase-arprotein-
ase inhibitor ILMA was relatively unimportant, pro-
vided that ovalbumin was not added; addition of
ovalbumin gave rise to higher results (tab. 3
column 2).
Leukocyte destruction during haemodialysis can be
monitored using these assays (18, 19). Studies were
performed before and after haemodialysis, to test the
assays for expected increases in lactoferrin and elas-
tase complexes (see tab. 5). The relationship of elas-
tase-cii-proteinase inhibitor complexes to lactoferrin
was studied in these patients, as the literature mainly
deals with elastase. The studies were performed as a
prerun for testing leukocyte destruction using differ-
ent haemodialysis membranes.
Unfortunately, commercial kits for elastase-arpro-
teinase inhibitor complexes are at present expensive
and time consuming (see tab. la) although the pro-
ducer has announced that a "rapid-version" of the
assay will soon be available. The assay developed here
correlated well with the commercial assay on plasma
samples from infants, as figure 3 shows.
In measuring these two analytes, we monitor a par-
adox, inasmuch as the elastase released is capable of
digesting lung tissue, when not complexed with aj-
proteinase inhibitor. On the other hand, lactoferrin
has a bacteriostatic action (18 — 19) and promotes
polymorphonuclear leukocyte adhesiveness (21).
The possibility cannot be excluded that lactoferrin
also plays a role in removing active oxygen species
such as free radicals and Superoxide ions. It has been
found that transferrin and ferritin are also elevated
in bronchoalveolar lavage from such patients (23).
All three proteins contain trivalent iron, which can
be reduced to bivalent iron by active oxygen anions
and radicals. In conclusion, assays are described for
two components of polymorphonuclear leukocytes.
Although the aim was to set up assays for monitoring
cases of neonatal sepsis, it is possible to answer other
questions regarding leukocyte activity and destruction
by measuring these two compounds. Especially im-
portant is the fact that these assays provide reliable
results of leukocyte involvement within an hour of
receiving samples, which is crucial in neonatal inten-
sive care.
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